These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 34949121

  • 1. Laboratory monitoring to reduce adverse drug-related events: a mixed methods study.
    Harrison TN, Reynolds K, Hahn EE, Munoz-Plaza CE, Yi DK, Fischer H, Luong TQ, Sim JJ, Brettler J, Handler J, Mittman BS, Singh H, Kanter MH, Danforth KN.
    J Manag Care Spec Pharm; 2022 Jan; 28(1):16-25. PubMed ID: 34949121
    [Abstract] [Full Text] [Related]

  • 2. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G, Annis IE, Farley JF, Mahendraratnam N, Hickson RP, Stürmer T, Robinson JG.
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [Abstract] [Full Text] [Related]

  • 3. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, Lafata JE, Roblin D, Davis RL, Gunter MJ, Platt R.
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
    [Abstract] [Full Text] [Related]

  • 4. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations.
    Parikh RV, Nash DM, Brimble KS, Markle-Reid M, Tan TC, McArthur E, Khoshniat-Rad F, Sood MM, Zheng S, Pravoverov L, Nesrallah GE, Garg AX, Go AS.
    Circ Cardiovasc Qual Outcomes; 2020 Sep; 13(9):e006415. PubMed ID: 32873054
    [Abstract] [Full Text] [Related]

  • 5. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF.
    Cochrane Database Syst Rev; 2014 Apr 29; (4):CD007004. PubMed ID: 24782282
    [Abstract] [Full Text] [Related]

  • 6. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
    Whitlock R, Leon SJ, Manacsa H, Askin N, Rigatto C, Fatoba ST, Farag YMK, Tangri N.
    Nephrol Dial Transplant; 2023 Oct 31; 38(11):2503-2516. PubMed ID: 37309038
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
    An J, Wei R, Zhou H, Luong TQ, Gould MK, Mefford MT, Harrison TN, Creekmur B, Lee MS, Sim JJ, Brettler JW, Martin JP, Ong-Su AL, Reynolds K.
    J Am Heart Assoc; 2021 Feb 02; 10(3):e019669. PubMed ID: 33307964
    [Abstract] [Full Text] [Related]

  • 8. Accepting Medication Therapy Management Recommendations to Add ACEIs or ARBs in Diabetes Care.
    Hurwitz JT, Grizzle AJ, Augustine J, Rehfeld R, Wild A, Abraham I.
    J Manag Care Spec Pharm; 2016 Jan 02; 22(1):40-8. PubMed ID: 27015050
    [Abstract] [Full Text] [Related]

  • 9. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With Outcomes After Acute Kidney Injury.
    Brar S, Ye F, James MT, Hemmelgarn B, Klarenbach S, Pannu N, Interdisciplinary Chronic Disease Collaboration.
    JAMA Intern Med; 2018 Dec 01; 178(12):1681-1690. PubMed ID: 30422153
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007751. PubMed ID: 21975774
    [Abstract] [Full Text] [Related]

  • 11. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients: A Nationwide Population-Based Cohort Study.
    Chien SC, Ou SM, Shih CJ, Chao PW, Li SY, Lee YJ, Kuo SC, Wang SJ, Chen TJ, Tarng DC, Chu H, Chen YT.
    Medicine (Baltimore); 2015 Oct 05; 94(43):e1751. PubMed ID: 26512568
    [Abstract] [Full Text] [Related]

  • 12. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
    Bainey KR, Rahim S, Etherington K, Rokoss ML, Natarajan MK, Velianou JL, Brons S, Mehta SR, CAPTAIN Investigators.
    Am Heart J; 2015 Jul 05; 170(1):110-6. PubMed ID: 26093871
    [Abstract] [Full Text] [Related]

  • 13. No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.
    Gilbert CJ, Gomes T, Mamdani MM, Hellings C, Yao Z, Garg AX, Wald R, Harel Z, Juurlink DN.
    Can J Cardiol; 2013 May 05; 29(5):586-91. PubMed ID: 23541666
    [Abstract] [Full Text] [Related]

  • 14. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R, Rios P, Baldovinos G, Chichet MA, Perg N, Sola L, Saona G, De Souza N, Lamadrid V, Gadola L.
    Nephron; 2019 May 05; 143(2):100-107. PubMed ID: 31203280
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and the risk of major adverse cardiac events in patients with diabetes and prior stroke: a nationwide study.
    Shih CJ, Chen HT, Chao PW, Kuo SC, Li SY, Yang CY, Tarng DC, Ou SM, Chen YT.
    J Hypertens; 2016 Mar 05; 34(3):567-74; discussion 575. PubMed ID: 26703918
    [Abstract] [Full Text] [Related]

  • 16. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
    Wang PT, Huang YB, Lin MY, Chuang PF, Hwang SJ.
    Kaohsiung J Med Sci; 2012 Sep 05; 28(9):477-83. PubMed ID: 22974666
    [Abstract] [Full Text] [Related]

  • 17. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
    Shih CJ, Chu H, Ou SM, Chen YT.
    Int J Cardiol; 2015 Nov 15; 199():283-9. PubMed ID: 26218587
    [Abstract] [Full Text] [Related]

  • 18. Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury.
    Gayat E, Hollinger A, Cariou A, Deye N, Vieillard-Baron A, Jaber S, Chousterman BG, Lu Q, Laterre PF, Monnet X, Darmon M, Leone M, Guidet B, Sonneville R, Lefrant JY, Fournier MC, Resche-Rigon M, Mebazaa A, Legrand M, FROG-ICU investigators.
    Intensive Care Med; 2018 May 15; 44(5):598-605. PubMed ID: 29766216
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients.
    Zhang L, Zeng X, Fu P, Wu HM.
    Cochrane Database Syst Rev; 2014 Jun 23; 2014(6):CD009120. PubMed ID: 24953826
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
    An J, Niu F, Sim JJ.
    Pharmacotherapy; 2021 Dec 23; 41(12):998-1008. PubMed ID: 34655484
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.